Mesa Laboratories (MLAB) Q1 FY27 earnings call

Mesa Laboratories delivered a strong operational turnaround in Q1 FY27, with positive organic revenue growth and significant adjusted operating income expansion, driven by improved performance in BPD and other segments. The new CEO emphasized a focus on execution and capital reallocation to high-return businesses, while actively managing the portfolio and committing to full-year guidance in November. Despite SDC's delivery challenges, the underlying demand remains healthy, and the company made substantial progress on deleveraging.